CYTOMX THERAPEUTICS INC. - COMMON STOCK

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

26 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference

17 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

05 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

05 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

22 Dec 2022 17:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

20 Dec 2022 17:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

07 Dec 2022 16:30:00 By Nasdaq GlobeNewswire

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

17 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

08 Nov 2022 16:10:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

07 Nov 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming November Investor Conferences

02 Nov 2022 16:15:01 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022

01 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249

12 Sep 2022 08:00:02 By Nasdaq GlobeNewswire

CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051

07 Sep 2022 18:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

04 Aug 2022 16:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences

03 Aug 2022 08:00:02 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

28 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

CytomX Therapeutics Provides Strategic Update

13 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

06 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

16 Jun 2022 08:00:01 By Nasdaq GlobeNewswire